ストックスクリーナーアプリを入手
5.69
2.57%
-0.15
アフターアワーズ：
5.69
Solid Biosciences Inc (SLDB) 最新ニュース
Aug Reactions: Is Solid Biosciences Inc stock a buy before product launches2025 AllTime Highs & Risk Controlled Stock Pick Alerts - moha.gov.vn
Can Solid Biosciences Inc. stock rebound after recent weaknessWeekly Loss Report & Capital Efficiency Focused Ideas - DonanımHaber
Is Solid Biosciences Inc. stock a buy before product launchesJuly 2025 Setups & Smart Investment Allocation Tips - DonanımHaber
Update Report: Is Solid Biosciences Inc. stock a bargain at current levels2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Solid Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
Gene Therapy Milestones And Collaborations Keep Solid Biosciences In Focus - RTTNews
Solid Biosciences (SLDB) Sees Duchenne Screening Advancement in US - GuruFocus
Solid Biosciences stock rises after Duchenne added to newborn screening list - Investing.com
Solid Biosciences Supports Duchenne Muscular Dystrophy Inclusion in U.S. Newborn Screening Recommendations - Quiver Quantitative
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services - The Manila Times
U.S. newborns will now be screened for Duchenne muscular dystrophy - Stock Titan
Solid Biosciences (SLDB) Gains Attention with Duchenne Muscular Dystrophy Inclusion - GuruFocus
Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy - Finviz
Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy - Insider Monkey
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum - GlobeNewswire
Bollard Group LLC Acquires New Holdings in Solid Biosciences Inc. $SLDB - MarketBeat
Needham & Company LLC Upgrades Solid Biosciences (NASDAQ:SLDB) to Moderate Buy - MarketBeat
Geode Capital Management LLC Purchases 979,294 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) COO Sells 4,932 Shares of Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) CEO Sells 10,808 Shares - MarketBeat
Jessie Hanrahan Sells 4,483 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences CEO Cumbo sells $55k in shares By Investing.com - Investing.com Canada
Solid Biosciences CEO Cumbo sells $55k in shares - Investing.com India
Solid Biosciences Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Benzinga
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Solid Biosciences (SLDB) Receives Buy Rating Amid Competitive Ad - GuruFocus
SLDB Receives "Buy" Rating from Needham with $16 Target Price | SLDB Stock News - GuruFocus
How Solid Biosciences Inc. stock performs in rising dollar environment2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status - Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences (Nasdaq: SLDB) issues 23,284 RSUs under 2024 inducement plan - Stock Titan
Solid Biosciences' SGT-212 Receives Rare Pediatric Disease Designation to Treat Friedreich's Ataxia - marketscreener.com
Solid Biosciences receives FDA rare pediatric disease designation for SGT-212 dual route of administration gene therapy - marketscreener.com
Solid Biosciences (SLDB) Gains Key FDA Designation for Gene Ther - GuruFocus
Solid Biosciences Receives FDA Rare Pediatric Disease and Fast Track Designations for SGT-212, a Novel Gene Therapy for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia - The Manila Times
Solid Biosciences Receives FDA Rare Pediatric Disease - GlobeNewswire
Franklin Resources Inc. Has $7.79 Million Position in Solid Biosciences Inc. $SLDB - MarketBeat
Is Solid Biosciences Inc. stock a bargain at current levels2025 Volatility Report & AI Enhanced Trading Alerts - moha.gov.vn
UBS Reaffirms Their Buy Rating on Credit Agricole (0HAI) - The Globe and Mail
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences (SLDB) Stock Analysis Report | Financials & Insights - Benzinga
Can Kennametal India Limited Deliver Relative Outperformance to SectorDebt-to-Equity Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Is Solid Biosciences Inc a good long term investmentTake Profit Strategies & Free Discover Dynamic Stocks - earlytimes.in
Using Bollinger Bands to evaluate Solid Biosciences Inc.July 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
How to forecast Solid Biosciences Inc. trends using time seriesGap Up & Weekly Market Pulse Updates - newser.com
What insider trading reveals about Solid Biosciences Inc. stockJuly 2025 Trends & Intraday High Probability Alerts - newser.com
Candlestick signals on Solid Biosciences Inc. stock todayMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
0.36%
0.72%
大文字化:
|
ボリューム (24 時間):